# Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency

> **NCT03667300** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 209 (actual)

## Conditions studied

- Type2 Diabetes Mellitus
- Albuminuria
- Renal Insufficiency

## Interventions

- **DRUG:** Evogliptin
- **DRUG:** Linagliptin

## Key facts

- **NCT ID:** NCT03667300
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-16
- **Primary completion:** 2019-05-14
- **Final completion:** 2019-05-14
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03667300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03667300, "Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03667300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*